For patients with HER2+ early breast cancer in whom a pathologic complete response is determined in the surgical specimen after completion of neoadjuvant trastuzumab and pertuzumab plus chemotherapy, the standard of care is trastuzumab for a total of 1 year (strong recommendation). The gene discussed is ERBB2; the disease is breast carcinoma.